HealthQuill
Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.
Drugs Health Pharma

Jazz Pharma’s oral drug for a type of brain tumour gets US approval 

Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.

Read More
Hanuman complex is very much implied in positive psychology in this sense. It helps individuals to rediscover their hidden potential. Rooted in Hanuman’s journey, literally across the sea of emotions, self-doubt and diffidence, it reminds us that when people are seen, heard and believed in, they fly.
Health Medical Opinion

Hanuman Complex: An Indian take on positive psychology and its human effect

Hanuman complex is very much implied in positive psychology in this sense. It helps individuals to rediscover their hidden potential. Rooted in Hanuman’s.

Read More
The Gates Foundation will support more than 40 innovations in five chronically underfunded areas in women’s health by spending $2.5 billion over the next five years.
Drugs Health Pharma

Gates Foundation to spend $2.5 billion on women’s health innovations

The Gates Foundation will support more than 40 innovations in five chronically underfunded areas in women’s health by spending $2.5 billion over the.

Read More
A 15-minute fast walk helped reduce mortality by 20%, mostly in low-income Black individuals in the US, a study finds.
Health Medical Research

A 15-minute brisk walk may cut mortality rate by 20%: Vanderbilt

A 15-minute fast walk helped reduce mortality by 20%, mostly in low-income Black individuals in the US, a study finds.

Read More
The US Food and Drug Administration has approved Nuvation Bio Inc.’s medicine for adults who have a rare type of lung cancer caused by a specific genetic change.
Health Research

Physicians using AI viewed as less competent and trustworthy

HQ Team August 2, 2025: A new study conducted by Moritz Reis from the University of Wuerzburg in Germany and colleagues has shed.

Read More
Biogen Inc., a US biotechnology company, has got marketing authorisation from the European medicines regulator for its drug to treat neurodegenerative disease, amyotrophic lateral sclerosis.
Health Research

Not all low-grade prostate cancers are low risk: New study finds 30% risk

HQ Team August 2, 2025: A study published in JAMA Oncology is challenging the conventional belief that men diagnosed with Grade Group One.

Read More
The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious kidney diseases.
Drugs Health Pharma

FDA approves Apellis’ therapy to treat two serious, rare kidney diseases

HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious.

Read More
Dementia patients are diagnosed on average 3.5 years after symptoms are first noticed, and it takes an even longer time for patients with early-onset of the disease, a global study by researchers at the University College London finds.
Health Medical Research

Dementia diagnosis takes 3.5 years after first symptoms surface: UCL study

HQ Team July 29, 2025: Dementia patients are diagnosed on average 3.5 years after symptoms are first noticed, and it takes an even.

Read More
The US Food and Drug Administration cleared PTC Therapeutics’ sepiapterin for treating children and adults with a rare genetic condition where the body cannot break down a part of protein called phenylalanine, which comes from foods like meat, eggs, and milk.
Drugs Health Pharma

US regulator clears PTC’s medicine to treat a rare genetic metabolic disease 

HQ Team July 29, 2025: The US Food and Drug Administration cleared PTC Therapeutics’ sepiapterin for treating children and adults with a rare.

Read More
Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the Chinese company’s 12 potential medicines.
Drugs Health Pharma

GSK inks $500m deal with Jiangsu Hengrui for 12 potential medicines

HQ Team July 28, 2025: Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the.

Read More